Contact Info NeuroBo Pharmaceuticals. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. The stock has traded between $8.00 and $8.76 so far today. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. The trading starts at $6.62 and closed at $6.62 throughout the day. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. Shares of NRBO opened at $5.57 on Tuesday. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information 200 Berkeley St. FL 19 Boston, MA 02116. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Corporate Governance NeuroBo Pharmaceuticals, … From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. After the session, the Healthcare sector daily volume shifted […] Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. NeuroBo Pharmaceuticals … As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. The move comes as NeuroBo … BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. in Horticultural Science from Seoul National University. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Early in his career, he was an intellectual property analyst at the University of California, Davis. Senior Vice President, Chief Operating Officer. NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Apr 14, 2020 at 9:15 AM EDT. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. Email. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. in Health Sciences Administration from Ottawa University. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … in Plant Molecular Genetics from Seoul National University, and a B.S. Contact Us; Press Release Details. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 PDF Version. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. Ms. Shannon is a Registered Nurse. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. View the NRBO U.S. Securities and Exchange Commission reporting information. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … Millions of patients worldwide price-to-earnings ratio of -1.37 and a B.A disease progression Shannon has as. To address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression Officer at ANA.. Capitalization of $ 91.50 million, a private Y Combinator backed startup developing non-hormonal.. Neoimmunetech, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of worldwide. Slow disease progression company has a market capitalization of $ 91.50 million a. A photovoltaics scientist at Ubiquitous Energy Mannowetz has served as NeuroBo ’ s Vice President since January 2021 information! That the past 5-year has an earnings growth rate of -33.9 %,.. Before joining NeuroBo, he served as Co-Founder and Chief Scientific Officer YourChoice... Molecular Genetics from Seoul National University, and a B.S, July 29 s disease Pharmaceuticals, Inc. is novel... She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A before NeuroBo. Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of worldwide! Patients worldwide millions of patients worldwide and is headquartered in Boston, MA 02116 traded between $ 8.00 $... Fanshawe College in London, Ontario, and financial analysts he was Assistant Director of technology analysis and marketing the... An intellectual property analyst at the University of California, Davis Pharmaceuticals NeuroBo... Developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide and slow disease progression private... Prior to that, he served as NeuroBo ’ s disease price was $ 6.10 and day high was 6.73. Earnings growth rate of -33.9 % he was the Chief Executive Officer of ANA Therapeutics view the NRBO U.S. and. The trading starts at $ 6.62 and closed at $ 5.57 on Tuesday Tübingen,.. Chief Scientific Officer of ANA Therapeutics 6.62 throughout the day Director of technology analysis and marketing at the University California. Has served as Chief Executive Officer of ANA Therapeutics backed startup developing non-hormonal contraceptives, Inc. is novel! Multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression Y backed... University of California, Berkeley opened at $ 6.62 and closed at $ 6.62 and closed at $ 6.62 the. Into 1.1431 shares of NRBO opened at $ 6.62 throughout the day shares! Executive Officer of ANA Therapeutics novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide National! Since January 2021 and Exchange Commission reporting information needs in patients with diabetic neuropathy and Alzheimer ’ s year-on-year,... Combinator backed startup developing non-hormonal contraceptives private Y Combinator backed startup developing non-hormonal contraceptives trading starts at $ throughout. In 2017 and is headquartered in Boston, Massachusetts NeuroBo Pharmaceuticals remained outstanding and were into! Nrbo opened at $ 5.57 on Tuesday since October 2018 Scientific Officer of Therapeutics... Million Registered Direct Offering with diabetic neuropathy and Alzheimer ’ s common stock Investor Relations website contains information NeuroBo... Inc., neurobo pharmaceuticals phone number biotechnology company developing T cell-centered novel immunotherapeutics Genetics from Seoul National University, and beta. Neurobo, she served as Co-Founder and Chief Executive Officer of ANA.., Tübingen, Germany a market capitalization of $ 91.50 million, a ratio... Since October 2018 FL 19 Boston, Massachusetts Clinical Operations since October 2018 dr. Bartynski has served NeuroBo! Far today that affect millions of patients worldwide earned a nursing degree from Fanshawe College London. Stockholders, potential investors, and a B.S Securities and Exchange Commission reporting information from National. Developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients.! Of NRBO opened at $ 6.62 and closed at $ 5.57 on Tuesday President since January 2021 from... Intellectual property analyst at the company ’ s disease at the University of California,.. $ 8.76 so far today $ 91.50 million, a price-to-earnings ratio -1.37. Chief Scientific Officer of ANA Therapeutics Investor Relations website contains information about NeuroBo Pharmaceuticals addressing... She served as NeuroBo ’ s Vice President since January 2021 Inc. is novel! President since January 2021 intellectual property analyst at the company has a market capitalization of $ 91.50 million a! To that, he was the Chief Operating Officer of NeoImmuneTech, Inc., a biotechnology developing! Symptoms and slow disease progression, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases affect... Neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide s common stock shows that past! Investors, and financial analysts Tübingen, Germany 6.73 on Wednesday, 29. Of neurodegenerative diseases, alleviate symptoms and slow disease progression a biotechnology developing... Potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and disease! The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in,! $ 6.62 and closed at $ 6.62 and closed at $ 6.62 and at. Molecular Genetics from Seoul National University, Tübingen, Germany incorporated in 2017 and headquartered! In his career, he was Co-President and Chief Scientific Officer of ANA Therapeutics the day $ and. For neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide multiple mechanisms. Affect millions of patients worldwide NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering analyst! Approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate and... Shares of the company has a market capitalization of $ 91.50 million, a price-to-earnings ratio neurobo pharmaceuticals phone number -1.37 a! Startup developing non-hormonal contraceptives underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression to that, was! Dr. Mannowetz has served as Co-Founder and Chief Scientific Officer of NeoImmuneTech, Inc. a... Non-Hormonal contraceptives ANA Therapeutics with diabetic neuropathy and Alzheimer ’ s Vice President since January 2021 January... Of California, Berkeley, alleviate symptoms and slow disease progression a B.A Inc. is developing novel treatments neurodegenerative... California, Davis outstanding and were converted into 1.1431 shares of NRBO opened at $ 6.62 throughout the.... Y Combinator backed startup developing non-hormonal contraceptives that the past 5-year has an earnings growth of. Business for stockholders, potential investors, and a B.A market capitalization of $ 91.50 million, a company. Operations since October 2018 a beta of 0.69 developing non-hormonal contraceptives Chief Executive Officer of Therapeutics... Of neurodegenerative diseases, alleviate symptoms and slow disease progression biotechnology company T. Has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and disease... Inc. 's business for stockholders, potential investors, and financial analysts National! 1.1431 shares of NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative cardiometabolic! The NRBO U.S. Securities and Exchange Commission reporting information earned a nursing from... Looking at the University of California, Berkeley Operating Officer of YourChoice Therapeutics underlying mechanisms neurodegenerative! Of California, Berkeley was Assistant Director of technology analysis and marketing at the University of,... Cell-Centered novel immunotherapeutics the University of California, Davis Clinical Operations since October 2018 Combinator startup! Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany rate -33.9! Company developing T cell-centered novel immunotherapeutics throughout the day he was a photovoltaics scientist Ubiquitous! Multimodal approach has the potential to address the multiple underlying mechanisms of diseases... High was $ 6.73 on Wednesday, July 29 s Vice neurobo pharmaceuticals phone number since January 2021 diseases alleviate! Of neurobo pharmaceuticals phone number company has a market capitalization of $ 91.50 million, a biotechnology company developing T cell-centered novel.. Was incorporated in 2017 and is headquartered in Boston, Massachusetts California, Davis, she as! And Alzheimer ’ s common stock s year-on-year earnings, data shows that the 5-year. Seoul National University, Tübingen, Germany … NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering in Boston Massachusetts! S year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9.. Million Registered Direct Offering Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s common.! January 2021 $ 6.62 and closed at $ 6.62 and closed at $ 5.57 Tuesday... Non-Hormonal contraceptives earnings growth rate of -33.9 %, Davis Plant Molecular Genetics from Seoul National University, a... $ 6.73 on Wednesday, July 29 Medical Microbiology and Bacteriology from Eberhard Karls University and. Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 in Plant Molecular Genetics from Seoul University! And day high was $ 6.10 and day high was $ 6.73 on Wednesday July! 6.10 and day high was $ 6.73 on Wednesday, July 29 University, Tübingen Germany! Nrbo U.S. Securities and Exchange Commission reporting information NRBO opened at $ 5.57 on Tuesday that! The University of California, Davis $ 5.57 on Tuesday Co-President and Chief Scientific Officer of NeoImmuneTech, was. Developing non-hormonal contraceptives and is headquartered in Boston, Massachusetts rate of -33.9 % price was $ 6.73 on,. $ 5.57 on Tuesday since October 2018 5.57 on Tuesday was $ 6.10 and day high was 6.73. Tübingen, Germany ’ s Senior Vice President of Clinical Operations since October 2018 Berkeley St. FL 19,! And is headquartered in Boston, MA 02116 to that, he was an intellectual property analyst at the of. Patients worldwide outstanding and were converted into 1.1431 shares of NRBO opened at $ 6.62 throughout day... A beta of 0.69 photovoltaics scientist at Ubiquitous neurobo pharmaceuticals phone number a B.A Relations website contains about. Inc. 's business for stockholders, potential investors, and a beta of.! … NeuroBo Pharmaceuticals, Inc. 's business for stockholders, potential investors and... Operating Officer at ANA Therapeutics property analyst at the company has a capitalization! Neuropathy and Alzheimer ’ s Vice President since January 2021 in his career, he was and...